[go: up one dir, main page]

WO2006131649A3 - Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques - Google Patents

Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques Download PDF

Info

Publication number
WO2006131649A3
WO2006131649A3 PCT/FR2006/001297 FR2006001297W WO2006131649A3 WO 2006131649 A3 WO2006131649 A3 WO 2006131649A3 FR 2006001297 W FR2006001297 W FR 2006001297W WO 2006131649 A3 WO2006131649 A3 WO 2006131649A3
Authority
WO
WIPO (PCT)
Prior art keywords
bioavailability
increase
fumagillin
derivatives
macrocyclic lactones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2006/001297
Other languages
English (en)
Other versions
WO2006131649A2 (fr
Inventor
Michel Alvinerie
Jacques Dupuy
Anne Lespine
Jean-Francois Sutra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Recherche Agronomique INRA
Original Assignee
Institut National de la Recherche Agronomique INRA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Recherche Agronomique INRA filed Critical Institut National de la Recherche Agronomique INRA
Priority to EP06764749A priority Critical patent/EP1888116A2/fr
Priority to BRPI0611642-6A priority patent/BRPI0611642A2/pt
Priority to AU2006256616A priority patent/AU2006256616A1/en
Priority to CA002611201A priority patent/CA2611201A1/fr
Priority to US11/917,031 priority patent/US20080200402A1/en
Priority to MX2007015504A priority patent/MX2007015504A/es
Publication of WO2006131649A2 publication Critical patent/WO2006131649A2/fr
Publication of WO2006131649A3 publication Critical patent/WO2006131649A3/fr
Anticipated expiration legal-status Critical
Priority to US12/975,410 priority patent/US20110144045A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation de la fumagilline, et de ses dérivés analogues, en tant qu'inhibiteurs des transporteurs cellulaires, tels que les transporteurs ABC, et plus particulièrement de la P-glycoprotéine, afin d'augmenter la biodisponibilité de principes actifs susceptibles d'être utilisés dans le traitement de pathologies telles que les cancers ou les maladies parasitaires, et en particulier afin d'augmenter la biodisponibilité des lactones macrocycliques.
PCT/FR2006/001297 2005-06-08 2006-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques Ceased WO2006131649A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP06764749A EP1888116A2 (fr) 2005-06-08 2006-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques
BRPI0611642-6A BRPI0611642A2 (pt) 2005-06-08 2006-06-08 utilização da fumagilina e de seus derivados para aumentar a biodisponibilidade das lactonas macrocìclicas
AU2006256616A AU2006256616A1 (en) 2005-06-08 2006-06-08 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
CA002611201A CA2611201A1 (fr) 2005-06-08 2006-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques
US11/917,031 US20080200402A1 (en) 2005-06-08 2006-06-08 Use Of Fumagillin And The Derivatives Thereof To Increase The Bioavilability Of The Macrocyclic Lactones
MX2007015504A MX2007015504A (es) 2005-06-08 2006-06-08 Uso de fumagilina y sus derivados para aumentar la biodisponibilidad de lactonas macrociclicas.
US12/975,410 US20110144045A1 (en) 2005-06-08 2010-12-22 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0505829 2005-06-08
FR0505829A FR2886855B1 (fr) 2005-06-08 2005-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/975,410 Division US20110144045A1 (en) 2005-06-08 2010-12-22 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones

Publications (2)

Publication Number Publication Date
WO2006131649A2 WO2006131649A2 (fr) 2006-12-14
WO2006131649A3 true WO2006131649A3 (fr) 2007-06-21

Family

ID=35064492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/001297 Ceased WO2006131649A2 (fr) 2005-06-08 2006-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques

Country Status (9)

Country Link
US (2) US20080200402A1 (fr)
EP (1) EP1888116A2 (fr)
AU (1) AU2006256616A1 (fr)
BR (1) BRPI0611642A2 (fr)
CA (1) CA2611201A1 (fr)
FR (1) FR2886855B1 (fr)
MX (1) MX2007015504A (fr)
WO (1) WO2006131649A2 (fr)
ZA (1) ZA200710600B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009374A1 (fr) 2008-07-18 2010-01-21 Zafgen, Inc. Procédés de traitement d'un sujet en surpoids ou obèse
WO2010065883A2 (fr) 2008-12-04 2010-06-10 Zafgen Corporation Procédés de traitement d'un sujet présentant un état de surpoids ou d'obésité
WO2010065877A2 (fr) 2008-12-04 2010-06-10 Zafgen Corporation Procédés de traitement d'un sujet en surpoids ou obèse
KR20120083905A (ko) 2009-10-09 2012-07-26 자프겐 코포레이션 비만의 치료에 사용하기 위한 설폰 화합물
JP5827239B2 (ja) 2010-01-08 2015-12-02 ザフゲン，インコーポレイテッド フマギロール型化合物並びにその製造方法及び使用方法
WO2011085198A1 (fr) 2010-01-08 2011-07-14 Zafgen Corporation Inhibiteur de metap-2 pour utilisation dans le traitement d'une hypertrophie bénigne de la prostate (bph)
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
EP2595988B1 (fr) 2010-07-22 2014-12-17 Zafgen, Inc. Composés tricycliques et procédés pour les préparer et les utiliser
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
BR112013013411A2 (pt) 2010-11-29 2016-09-13 Zafgen Inc tratamento de obesidade usando administração não diária de 6-0-(4-dimetilaminoetxi) cinamoil fumagilol
KR20140006888A (ko) 2011-01-26 2014-01-16 자프겐 인크. 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
EP2683706B1 (fr) 2011-03-08 2018-02-21 Zafgen, Inc. Dérivés d'oxaspiro[2.5]octane et analogues
US9351988B2 (en) 2011-05-02 2016-05-31 Universite De Geneve Macrocyclic lactones and use thereof
JP5941981B2 (ja) 2011-05-06 2016-06-29 ザフゲン，インコーポレイテッド 三環式スルホンアミド化合物ならびにその製造および使用方法
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
CA2835261C (fr) 2011-05-06 2019-06-04 Zafgen, Inc. Composes tricycliques partiellement satures et leurs procedes de fabrication et d'utilisation
EP2763671A2 (fr) 2011-10-03 2014-08-13 Zafgen, Inc. Méthodes de traitement de troubles liés à l âge
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
WO2013169727A1 (fr) 2012-05-07 2013-11-14 Zafgen, Inc. Sel polymorphe de sel d'oxalate de 6-o-(4-dimethylaminoethoxy) cinnarnoyl fumagillol et ses procédés de production et d'utilisation
KR20150013222A (ko) 2012-05-08 2015-02-04 자프겐 인크. Metap2 저해제를 이용한 시상하부 비만의 치료
WO2013169860A1 (fr) 2012-05-09 2013-11-14 Zafgen, Inc. Composés de type fumagillol, leurs procédés de fabrication et d'utilisation
EA028367B1 (ru) 2012-11-05 2017-11-30 Зафджен, Инк. Способы лечения заболеваний печени
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
CA2890342A1 (fr) 2012-11-05 2014-05-08 Zafgen, Inc. Composes tricycliques et procedes de fabrication et d'utilisation associes
US9597309B2 (en) 2013-03-14 2017-03-21 Zafgen, Inc. Methods of treating renal disease and other disorders
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
ES2955137T3 (es) 2013-03-14 2023-11-28 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
AU2015218587B2 (en) 2014-02-24 2017-04-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
WO1994019946A1 (fr) * 1993-03-01 1994-09-15 Emory University Traitement de la keratoconjonctivite de microsporidia et d'acanthamoeba par application locale de fumagilline
EP0658342A1 (fr) * 1993-09-24 1995-06-21 Takeda Chemical Industries, Ltd. Composition pharmaceutique antineoplastique contenant des dérivées de fumagillol
WO1996030010A2 (fr) * 1995-03-27 1996-10-03 Sanofi Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales
EP0819430A1 (fr) * 1996-07-17 1998-01-21 Takeda Chemical Industries, Ltd. Inhibiteur de métastase ou réapparition des tumeurs
EP1258248A2 (fr) * 2001-05-18 2002-11-20 TAP Pharmaceutical Products, Inc. Traitement de tumeurs avec un dérivé de fumagillol et un autre agent antinéoplastique
WO2004039172A1 (fr) * 2002-10-31 2004-05-13 Szoke Annamaria Systeme d'administration par voie orale d'un medicament veterinaire et/ou systeme d'administration d'un additif alimentaire, procede de preparation et d'utilisation de ceux-ci

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
WO1994019946A1 (fr) * 1993-03-01 1994-09-15 Emory University Traitement de la keratoconjonctivite de microsporidia et d'acanthamoeba par application locale de fumagilline
EP0658342A1 (fr) * 1993-09-24 1995-06-21 Takeda Chemical Industries, Ltd. Composition pharmaceutique antineoplastique contenant des dérivées de fumagillol
WO1996030010A2 (fr) * 1995-03-27 1996-10-03 Sanofi Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales
EP0819430A1 (fr) * 1996-07-17 1998-01-21 Takeda Chemical Industries, Ltd. Inhibiteur de métastase ou réapparition des tumeurs
EP1258248A2 (fr) * 2001-05-18 2002-11-20 TAP Pharmaceutical Products, Inc. Traitement de tumeurs avec un dérivé de fumagillol et un autre agent antinéoplastique
WO2004039172A1 (fr) * 2002-10-31 2004-05-13 Szoke Annamaria Systeme d'administration par voie orale d'un medicament veterinaire et/ou systeme d'administration d'un additif alimentaire, procede de preparation et d'utilisation de ceux-ci

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRINYAEV V A ET AL: "Antitumor effect of avermectins", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 501, no. 1-3, 6 October 2004 (2004-10-06), pages 19 - 23, XP004587589, ISSN: 0014-2999 *
LESPINE A ET AL: "Role of the p-glycoprotein in the cellular efflux of macrocyclic lactones: Influence of interfering agents.", JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, vol. 26, no. Supplement 1, August 2003 (2003-08-01), & PROCEEDINGS OF THE 9TH INTERNATIONAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR VETERINARY PHARMACOLOG; LISBON, PORTUGAL; JULY 13-18, 2003, pages 161 - 162, XP008077611, ISSN: 0140-7783 *
WILHELMUS K R: "Antiparasitic drugs in ophthalmology", INTERNATIONAL OPHTHALMOLOGY CLINICS 1996 UNITED STATES, vol. 36, no. 2, 1996, pages 117 - 152, XP008077587, ISSN: 0020-8167 *

Also Published As

Publication number Publication date
FR2886855A1 (fr) 2006-12-15
FR2886855B1 (fr) 2009-07-17
ZA200710600B (en) 2009-05-27
BRPI0611642A2 (pt) 2010-09-28
AU2006256616A1 (en) 2006-12-14
EP1888116A2 (fr) 2008-02-20
CA2611201A1 (fr) 2006-12-14
US20080200402A1 (en) 2008-08-21
MX2007015504A (es) 2008-03-18
US20110144045A1 (en) 2011-06-16
WO2006131649A2 (fr) 2006-12-14

Similar Documents

Publication Publication Date Title
WO2006131649A3 (fr) Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques
PL1940249T3 (pl) Nowe formulacje rozpuszczalnych w tłuszczach składników aktywnych o wysokiej biodostępności
EP2450360A3 (fr) (S)-N-Méthylnaltrexone
ZA200705750B (en) Compositions and methods for stabilizing active pharmaceutical ingredients
WO2007086001A3 (fr) Nouveaux dérivés de pyridine
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
WO2007044084A3 (fr) Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation
WO2005123076A3 (fr) Compositions pharmaceutiques
WO2006099169A3 (fr) Nouvelles compositions de liposomes
WO2006013441A3 (fr) Utilisation de bacteries probiotiques dans la preparation de compositions topiques destinees a la protection de la peau
MY143795A (en) Tetrahydropyridoindole derivatives
WO2006124698A3 (fr) Traitement au dronabinol de nausees et vomissements induits par chimiotherapie differee
WO2011076209A3 (fr) Composition pharmaceutique comprenant un mélange de solvants et un dérivé de la vitamine d ou analogue
WO2006060515A3 (fr) Systeme permettant d'ameliorer l'absorption percutanee d'agents benefiques pour la peau
WO2009038095A1 (fr) Composition comprenant de la sésamine et de la vitamine b1
WO2004091591A3 (fr) Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives
WO2009059755A3 (fr) Nouveaux conjugués de neurturine pour une utilisation pharmaceutique
WO2006021001A3 (fr) Derives de polynorbornene amphiphiles et leurs methodes d'utilisation
WO2006075256A3 (fr) 9a-carbamoyl-y-aminopropyl- et 9a-thiocarbamoyl-y-aminopropyl-azalides a activite anti-paludique
AU2003290127A1 (en) 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level
SI1646378T1 (sl) Farmacevtski sestavki, ki vsebujejo askorbinsko kislino, za zdravljenje gliviäśnih superinfekcij ingliviäśnih recidivov
WO2007114946A3 (fr) Lieurs sensibles aux acides destinés à l'administration de médicaments
WO2004026319A3 (fr) Compositions pharmaceutiques utilisees pour le traitement de cancers
WO2007086943A3 (fr) Conjugués de la wortmannine et utilisations de ceux-ci
WO2008037740A3 (fr) Boisson appropriée pour retarder la dégénérescence cellulaire qui accompagne le vieillissement

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006764749

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/015504

Country of ref document: MX

Ref document number: 2611201

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 564101

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006256616

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006256616

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006256616

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006764749

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11917031

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0611642

Country of ref document: BR

Kind code of ref document: A2